Carine J M Doggen Selected Research

Stents

1/2022	Outcome after percutaneous coronary intervention with contemporary stents in patients with concomitant peripheral arterial disease: A patient-level pooled analysis of four randomized trials.
10/2021	Impact of prediabetes and diabetes on 3-year outcome of patients treated with new-generation drug-eluting stents in two large-scale randomized clinical trials.
1/2021	Acute myocardial infarction treated with novel Resolute Onyx and Orsiro stents in the randomized BIONYX trial.
1/2021	Coronary bifurcations treated with thin-strut drug-eluting stents: a prespecified analysis of the randomized BIO-RESORT trial.
11/2020	Thin Composite-Wire-Strut Zotarolimus-Eluting Stents Versus Ultrathin-Strut Sirolimus-Eluting Stents in BIONYX at 2 Years.
1/2019	Thin, Very Thin, or Ultrathin Strut Biodegradable or Durable Polymer-Coated Drug-Eluting Stents: 3-Year Outcomes of BIO-RESORT.
1/2019	Outcomes in Patients Treated With Thin-Strut, Very Thin-Strut, or Ultrathin-Strut Drug-Eluting Stents in Small Coronary Vessels: A Prespecified Analysis of the Randomized BIO-RESORT Trial.
12/2018	5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.
10/2018	Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial.
1/2018	Bioresorbable Polymer-Coated Orsiro Versus Durable Polymer-Coated Resolute Onyx Stents (BIONYX): Rationale and design of the randomized TWENTE IV multicenter trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Carine J M Doggen Research Topics

Disease

28	Thrombosis (Thrombus) 01/2021 - 10/2004
23	Myocardial Infarction 01/2021 - 09/2003
20	Venous Thrombosis (Deep-Vein Thrombosis) 10/2013 - 10/2004
7	Death (Near-Death Experience) 01/2021 - 10/2016
5	Chest Pain (Chest Pains) 03/2022 - 06/2015
5	Acute Coronary Syndrome 10/2018 - 11/2016
4	Coronary Artery Disease (Coronary Atherosclerosis) 03/2022 - 11/2016
4	Hemorrhage 10/2021 - 11/2017
4	Inflammation (Inflammations) 12/2018 - 03/2005
4	ST Elevation Myocardial Infarction 09/2018 - 11/2014
4	Neoplasms (Cancer) 05/2008 - 10/2004
3	Prediabetic State (Prediabetes) 10/2021 - 10/2018
3	Pain (Aches) 05/2017 - 05/2015
3	Coronary Disease (Coronary Heart Disease) 01/2017 - 06/2005
2	Cardiovascular Diseases (Cardiovascular Disease) 03/2022 - 03/2005
2	Atherosclerosis 01/2022 - 07/2009
2	Stroke (Strokes) 02/2021 - 11/2017
2	Diabetes Mellitus 01/2018 - 04/2014
2	Musculoskeletal Pain 05/2017 - 05/2015
2	Wounds and Injuries (Trauma) 12/2016 - 01/2008
1	Confusion (Bewilderment) 05/2022
1	Pathologic Constriction (Stenosis) 03/2022
1	Peripheral Arterial Disease 01/2022
1	Heart Failure 01/2020
1	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2018
1	Psoriatic Arthritis 01/2018
1	Stable Angina 01/2018
1	Hyperemia 04/2017
1	Renal Insufficiency (Renal Failure) 01/2015
1	Protein S Deficiency (Deficiency, Protein S) 10/2013
1	Out-of-Hospital Cardiac Arrest 10/2011
1	Vascular Remodeling 07/2009
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 07/2009

Drug/Important Bio-Agent (IBA)

6	zotarolimusIBA 01/2021 - 02/2014
6	PolymersIBA 12/2018 - 06/2015
6	factor V LeidenIBA 05/2008 - 02/2005
5	Everolimus FDA Link 01/2019 - 02/2014
5	Oral ContraceptivesIBA 05/2008 - 02/2005
4	Sirolimus (Rapamycin)FDA Link 01/2021 - 04/2014
4	Proteins (Proteins, Gene)FDA Link 07/2010 - 06/2009
4	Tissue Plasminogen Activator (Alteplase)FDA Link 07/2010 - 05/2007
4	PlasminogenIBA 07/2010 - 05/2007
3	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 09/2003
3	Analgesics (Analgesic Drugs)IBA 05/2017 - 05/2015
3	LipidsIBA 01/2017 - 10/2004
3	ElementsIBA 01/2017 - 06/2015
3	Blood Coagulation Factors (Coagulation Factor)IBA 04/2010 - 12/2006
3	Factor VIII (Coagulation Factor VIII)IBA 04/2010 - 06/2006
3	AntigensIBA 10/2009 - 03/2007
3	Carboxypeptidase B2 (Thrombin Activatable Fibrinolysis Inhibitor)IBA 07/2009 - 05/2007
2	CalciumIBA 03/2022 - 01/2022
2	CobaltIBA 10/2018 - 01/2018
2	ChromiumIBA 10/2018 - 01/2018
2	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 10/2018 - 11/2017
2	Clopidogrel (Plavix)FDA Link 10/2018 - 11/2017
2	TicagrelorIBA 10/2018 - 11/2017
2	EnzymesIBA 01/2018 - 03/2007
2	C-Reactive ProteinIBA 04/2017 - 03/2005
2	Plasminogen Activators (Plasminogen Activator)IBA 07/2010 - 05/2007
2	Plasminogen Activator Inhibitor 1IBA 07/2010 - 07/2009
2	Fibrinogen (Factor I)FDA Link 04/2010 - 01/2008
2	Tyr sulfate(1)- enkephalinamide-Leu (LETS)IBA 05/2009 - 06/2006
2	Messenger RNA (mRNA)IBA 03/2009 - 03/2005
2	Prothrombin (Factor II)IBA 10/2007 - 02/2005
2	CholesterolIBA 06/2005 - 10/2004
1	Pharmaceutical PreparationsIBA 05/2022
1	omega-Chloroacetophenone (Mace)IBA 03/2022
1	Phenobarbital (Luminal)FDA Link 03/2022
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2020
1	Pyridinolcarbamate (P23)IBA 01/2020
1	Angiotensin Receptor AntagonistsIBA 01/2020
1	DiureticsIBA 01/2020
1	Mineralocorticoid Receptor AntagonistsIBA 01/2020
1	Folic Acid (Vitamin M)FDA LinkGeneric 01/2018
1	Methotrexate (Mexate)FDA LinkGeneric 01/2018
1	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 11/2017
1	1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)IBA 04/2017
1	acetyltropic acid 4-pyridylmethylamideIBA 04/2017
1	Tobacco Smoke Pollution (Passive Smoking)IBA 01/2017
1	B 823-08IBA 10/2016
1	Protein SIBA 10/2013
1	Antifibrinolytic Agents (Antifibrinolytics)IBA 07/2010
1	Blood Group Antigens (Blood Groups)IBA 04/2010
1	beta 2-Glycoprotein I (Apolipoprotein H)IBA 10/2009
1	CoagulantsIBA 10/2009
1	Factor IX (Coagulation Factor IX)FDA LinkGeneric 05/2009
1	Indicators and Reagents (Reagents)IBA 03/2009
1	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 03/2009
1	Interleukin-1 (Interleukin 1)IBA 03/2009
1	Blood Proteins (Serum Proteins)IBA 01/2009
1	Protein CIBA 01/2009

Therapy/Procedure

25	Stents 01/2022 - 02/2014
17	Drug-Eluting Stents 10/2021 - 01/2015
14	Percutaneous Coronary Intervention 01/2022 - 11/2014
4	Aftercare (After-Treatment) 10/2021 - 06/2015
3	Pain Management 05/2017 - 05/2015
2	Therapeutics 02/2021 - 10/2004
1	Defibrillators (Defibrillator) 10/2011
1	Cardiopulmonary Resuscitation (CPR) 10/2011
1	Drug Therapy (Chemotherapy) 05/2008